Home › NDC Lookup › RxCUI directory › RxCUI 1922466

Safinamide 50 MG Oral Tablet — RxCUI 1922466

RxNorm drug concept · Semantic clinical drug
RxCUI 1922466 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1922466
Official nameSafinamide 50 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known assafinamide 50 MG (as safinamide mesylate 65.88 MG) Oral Tablet
FDA products mapped2
Package NDCs mapped6
Reported Medicaid activity (SDUD)26 prescriptions · 2 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Safinamide: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Levodopa/carbidopa is indeed the cornerstone of Parkinson's treatment, but over time many people start experiencing 'off' periods — times when the medication seems to wear off befo...
  • Why did my doctor add Xadago to my levodopa? I thought levodopa was the main treatment.
  • The biggest ones are other MAO inhibitors (like certain antidepressants or the antibiotic linezolid), opioid pain medicines like tramadol or codeine, most antidepressants in the tr...
  • There's a long list of medications I can't take with this. What are the most important ones to watch out for?
📖 Read our full Safinamide guide →

🕸️ Concept Web — How Safinamide 50 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Safinamide 50 MG Oral Tablet RxCUI 1922466

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Safinamide 1922448
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Xadago 1922467
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Safinamide Oral Tablet 1922465
    • Safinamide Oral Product 1922463
    • Safinamide Pill 1922464
    • Safinamide Oral Tablet [Xadago] 1922469
    • Xadago Oral Product 1922470
    • Xadago Pill 1922471
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Safinamide 50 MG SCDC · 1922462
  • Safinamide Oral Tablet SCDF · 1922465
  • Safinamide Oral Product SCDG · 1922463
  • Safinamide Pill SCDG · 1922464

Brand-Name Concepts

  • Safinamide 50 MG Oral Tablet [Xadago] SBD · 1922472
  • Safinamide 50 MG [Xadago] SBDC · 1922468
  • Safinamide Oral Tablet [Xadago] SBDF · 1922469
  • Xadago Oral Product SBDG · 1922470
  • Xadago Pill SBDG · 1922471
  • Xadago BN · 1922467

📦 FDA Products & Package NDCs

2 products · 6 package NDCs
6 package NDCs map to RxCUI 1922466 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
27505-0110-14 1 BLISTER PACK in 1 CARTON (27505-110-14) / 14 TABLET, FILM... Xadago MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc. 2017-05-08
27505-0110-30 1 BOTTLE in 1 CARTON (27505-110-30) / 30 TABLET, FILM COATE... Xadago MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc. 2017-05-08
27505-0110-90 1 BOTTLE in 1 CARTON (27505-110-90) / 90 TABLET, FILM COATE... Xadago MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc. 2017-05-08
27505-0111-14 1 BLISTER PACK in 1 CARTON (27505-111-14) / 14 TABLET, FILM... Xadago MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc. 2017-05-08
27505-0111-30 1 BOTTLE in 1 CARTON (27505-111-30) / 30 TABLET, FILM COATE... Xadago MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc. 2017-05-08
27505-0111-90 1 BOTTLE in 1 CARTON (27505-111-90) / 90 TABLET, FILM COATE... Xadago MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc. 2017-05-08
Observed labelers: MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc. (6) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.